Duragesic Pediatric Exclusivity: Diflucan Precedent Should Delay Mylan’s Generic, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
In a letter to FDA, J&J points to the Pfizer/Ranbaxy dispute over the scope of pediatric exclusivity for Diflucan in arguing that Mylan’s Paragraph IV certification for the fentanyl patch should be treated as a Paragraph II certification and subject to the innovator’s six-month pediatric extension.
You may also be interested in...
J&J Duragesic Patent Upheld; Pediatric Exclusivity Dispute Will Determine Timing Of Mylan Generic
Mylan claims it should be able to launch in July; J&J says the generic is blocked by pediatric exclusivity until January 2005. Mylan says J&J failed to sue within statutory 45-day period and so forfeits pediatric exclusivity protection.
Ranbaxy Diflucan Generic Launch Delayed Until July Under Court Ruling
Company's fluconazole ANDAs are subject to the six-month pediatric extension for Pfizer's patent on the antifungal, a federal court says.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.